Inflammatory disease in HLA-B27 transgenic rats

Immunological Reviews

Volumn 169, Issue , 1999, Pages 209-223

  Taurog, Joel D ^a   Maika, Shanna D ^a,c   Satumtira, Nimman ^a   Dorris, Martha L ^a   McLean, Ian Lachlan ^a   Yanagisawa, Hiromi ^a   Sayad, Alain ^b,d   Stagg, Andrew J ^a   Fox, Graham M ^a   O'Brien, Ann Le ^e   Rehman, Muhammad ^a   Zhou, Ming ^a,f   Weiner, Allison L ^a   Splawski, Judy B ^a,g   Richardson, James A ^b   Hammer, Robert E ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d Abou Jaoude Hospital   (Lebanon)

^e NORTHWICK PARK HOSPITAL   (United Kingdom)

^f BROOKLYN HOSPITAL CENTER   (United States)

^g UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA B27 ANTIGEN; IMMUNOGLOBULIN A; INTERLEUKIN 6; MESSENGER RNA; MUTANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTHRITIS; COLITIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATORY DISEASE; INTESTINE FLORA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REVIEW; SKIN DEFECT; SPONDYLOARTHROPATHY; TRANSGENIC ANIMAL;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGEN PRESENTATION; ARTHRITIS; CYTOKINES; DISEASE MODELS, ANIMAL; HLA-B27 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN A; INFLAMMATION; MUTATION; PEPTIDES; PHENOTYPE; RATS; RATS, INBRED STRAINS; SPONDYLITIS;

EID: 0032806580     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01317.x     Document Type: Review

References (83)

1. 1. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Eng J Med 1973;288:704-706.
2. 2. Brewerton DA, Hart FD, Caffrey M, Nicholls A, James DCO, Sturrock RD. Ankylosing spondylitis and HL A 27. Lancet 1973;1:904-907.
3. 3. Lopez de Castro JA. The pathogenetic role of HLA-B27 in chronic arthritis. Curr Opin Immunol 1998;10:59-66.
4. 4. Taurog JD. HLA-B27 subtypes, disease susceptibility, and peptide binding specificity. In: Calin A, Taurog JD, eds. The spondylarthriticles. Oxford, UK; Oxford University Press; 1998. p. 267-273.
5. 5. Krimpenfort P, Rudenko G, Hochstenbach F, Guessow D, Berns A, Plocgh H. Crosses of two independently derived transgenic mice demonstrate functional complementation of the genes encoding heavy (HLA-B27) and light (β 2 microglobulin) chains of HLA class I antigens. EMBO J 1987;6:1673-1676.
6. 6. Kievits F, Ivanyi P, Krimpenfort P, Berns A, Ploegh HL. HLA-restricted recognition of viral antigens in HLA transgenic mice. Nature 1987;329:447-449.
7. 7. Taurog JD, Lowen L, Forman J, Hammer RE. HLA-B27 in inbred and non-inbred transgenic mice. Cell surface expression and recognition as an alloantigen in the absence of human β 2-microglobulin. J Immunol 1988;141:4020-4023.
8. 8. Weiss EH, et al. Copy number and presence of human β-2-microglobulin control cell surface expression of HLA-B27 antigen in transgenic mice with a 2.5 kb B27 gene fragment. In: Egorov IK, David CS, eds. Transgenic mice and mutants in MHC research. Berlin: Springer-Verlag; 1990. p. 205-213.
9. 9. Nickerson CL, Luthra HL, Savarirayan S, David C. Susceptibility of HLA-B27 transgenic mice to Yersinia enterocolitica infection. Hum Immunol 1990;28:382-396.
10. 10. Taurog JD, et al. HLA-B27 transgenic mice as potential models of human disease. In: Egorov IK, David CS, eds. Transgenic mice and mutants in MHC research. Berlin: Springer-Verlag; 1990. p. 268-275.
11. 11. Hammer RE, Maika SD, Richardson JA, Tang J-P, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2-m; an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099-1112.
12. 12. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 1993;150:4168-4178.
13. 13. Hammer RE, Richardson JA, Simmons WA, White A, Breban M, Taurog JD. High prevalence of colorectal cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease. J Invest Med 1995;43:262-268.
14. 14. Yanagisawa H, Hammer RE, Taurog JD, Richardson JA. Characterization of psoriasiform and alopecic skin lesions in HLA-B27 transgenic rats. Am J Pathol 1995;147:955-964.
15. 15. Taurog JD, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-2364.
16. 16. Baggia S, et al. A novel model of bacterially-induced acute anterior uveitis in rats and lack of effect of HLA-B27 expression. J Invest Med 1997;45:295-301.
17. 17. Schmitt-Egenolf M, Boehncke WH, Christophers E, Stander M, Sterry W. Type I and type II psoriasis show a similar usage of T-cell receptor variable regions. J Invest Dermatol 1991;97:1053-1056.
18. 18. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992;70:1035-1048.
19. 19. Gao XM, et al. Homocysteine modification of HLA antigens and its immunological consequences. Eur J Immunol 1996;26:1443-1450.
20. 20. Whelan MA, Archer JR. Chemical reactivity of an HLA-B27 thiol group. Eur J Immunol 1993;23:3278-3285.
21. 21. Bowness P, Allen RL, McMichael AJ. HLA-B27 can form heavy chain homodimers in vitro and in vivo. Possible role of Cys 67. Arthritis Rheum 1998;41:S355.
22. 22. Sobao Y, Tsuchiya N, Takiguchi M, Tokunaga K. Overlapping peptide-binding specificities of HLA-B27 and B39 - evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies. Arthritis Rheum 1999;42:175-181.
23. 23. Colbert RA, Rowland-Jones SL, McMichael AJ, Frelinger JA. Allele-specific B pocket transplant in class I major histocompatibility complex protein changes requirement for anchor residue at P2 of peptide. Proc Natl Acad Sci USA 1993;90:6879-6883.
24. 24. Bowness P, Allen RL, Barclay DN, Jones EY, McMichael AJ. Importance of a conserved TCR J α-encoded tyrosine for T cell recognition of an HLA B27/peptide complex. Eur J Immunol 1998;28:2704-2713.
25. 25. Rath HC, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human β2 microglobulin transgenic rats. J Clin Invest 1996;98:945-953.
26. 26. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus and E. coli. Infect Immun (In press).
27. 27. Onderdonk AB, Richardson JA, Hammer RE, Taurog JD. Cecal microflora of HLA-B27 transgenic rats: correlation with inflammatory bowel disease. Infect Immun 1998;66:6022-6023.
28. 28. Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med 1993;178:1606-1616.
29. 29. Breban M, et al. T cells but not thymic exposure to HLA-B27 are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996;156:794-803.
30. 30. Ball J. Pathology and pathogenesis. In: Moll JMH, ed. Ankylosing spondylitis. Edinburgh: Churchill-Livingstone; 1980. p. 96-112.
31. 31. Eulderink F. Pathology of ankylosing spondylitis. Spine: State of the Art Reviews 1990;4:507-528.
32. 32. McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998;41:694-700.
33. 33. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998;352:1137-1140.
34. 34. Stagg AJ, Breban M, Hammer RE, Knight SC, Taurog JD. Defective dendritic cell function in a HLA-B27 transgenic rat model of spondyloarthropathy. Adv Exp Med Biol 1995;378:557-9.
35. 35. Powis SJ, et al. Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature 1992;357:211-215.
36. 36. Simmons WA, et al. Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. J Immunol 1996;156:1661-1667.
37. 37. Mornburg F, Roelse J, Howard JC, Butcher GW, Hammerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1994;367:648-651.
38. 38. Heemels MT, Schumacher TN, Wonigeit K, Ploegh HL. Peptide translocation by variants of the transporter associated with antigen processing. Science 1993;262:2059-2063.
39. 39. Zhou M, et al. The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J Exp Med 1998;188:877-886.
40. 40. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996;84:769-779.
41. 41. Hughes EA, Hammond C, Cresswell P. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc Natl Acad Sci USA 1997;94:1896-1901.
42. 42. Colbert RA, Mear JP, Zhu X. The B pocket contributes to misfolding and cytosolic degradation of HLA-B27. Arthritis Rheum 1998;41:S355.
43. 43. Boisgerault F, et al. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies. J Clin Invest 1996;98:2764-2770.
44. 44. Garcia F, Marina A, Albar JP, Lopez de Castro JA. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. Tissue Antigens 1997;49:23-28.
45. 45. Scofield RH, Kurien B, Gross T, Warren WL, Harley JB. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995;345:1542-1544.
46. 46. Parham P. Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis. Immunol Rev 1996;154:137-154.
47. 47. Strober W, Ludviksson BR, Fuss IJ. The pathogenesis of mucosal inflammation in murine models of iniflammatory bowel disease and Crohn disease. Ann Intern Med 1998;128:848-856.
48. 48. Bertrand V, et al. Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human β 2-microglobulin. Eur Cytokine Netw 1998;9:161-170.
49. 49. Gesualdo L, Emancipator SN, Kesselheim C, Lamm ME. Glomerular hemodynamics and eicosanoid synthesis in a rat model of IgA nephropathy. Kidney Int 1992;42:106-114.
50. 50. Archer JR. Ankylosing spondylitis, IgA, and transforming growth factors. Ann Rheum Dis 1995;54:544-546.
51. 51. Remmers EF, et al. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat Genet 1996;14:82-85.
52. 52. Kawahito Y, et al. Localization of quantitative trait loci regulating adjuvant-induced arthritis in rats: evidence for genetic factors common to multiple autoimmune diseases. J Immunol 1998;161:4411-4419.
53. 53. Brown MA, et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998;41:588-595.
54. 54. Van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-249.
55. 55. Braun J, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
56. 56. Jarvinen P. Occurrence of ankylosing spondylitis in a nationwide series of twins. Arthritis Rheum 1995;38:381-383.
57. 57. Brown MA, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997;40:1823-1828.
58. 58. Parker KC, Biddison WE, Coligan JE. Pocket mutations of HLA-B27 show that anchor residues act cumulatively to stabilize peptide binding. Biochemistry 1994;33:7736-7743.
59. 59. Galocha B, Lamas JR, Villadangos JA, Albar JP, Lopez de Castro JA. Binding of peptides naturally presented by HLA-B27 to the differentially disease associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Tissue Antigens 1996;48:509-518.
60. a suggests an allele-specific motif. Immunogenetics 1995;41:329-331.
61. 61. Powis SJ, et al. The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against C terminal trimming of peptides in the ER. Immunity 1996;4:159-165.
62. 62. Mielants H, Veys EM. The bowel and spondylarthritis: a clinical approach. In: Calin A, Taurog JD, eds. The spondylarthritides. Oxford, UK: Oxford University Press; 1998. p. 129-157.
63. 63. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-1367.
64. + TH1-like responses. J Clin Invest 1996;98:1010-1020.
65. 65. Uksila J, Toivanen P, Granfors K. Enteric infections and arthritis: bacteriological aspects. In: Calin A, Taurog JD, eds. The spondylarthritides. Oxford, UK: Oxford University Press; 1998. p. 167-177.
66. 66. Laitio P, Virtala M, Salmi M, Pelliniemi LJ, Yu DT, Granfors K. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur J Immunol 1997;27:1331-1338.
67. 67. Virtala M, Kirveskari J, Granfors K. HLA-B27 modulates the survival of Salmonella enteritidis in transfected L cells, possibly by impaired nitric oxide production. Infect Immun 1997;65:4236-4242.
68. 68. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996;183:1287-1292.
69. 69. Böcker U, Sartor RB. Mechanisms of arthritis associated with chronic intestinal inflammation. In: Calin A, Taurog JD, eds. The spondylarthritides. Oxford, UK: Oxford University Press; 1998. p. 207-222.
70. 70. Salmi M, Andrew DP, Butcher EC, Jalkanen S. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 1995;181:137-149.
71. 71. Kirveskari J, Jalkanen S, Maki-Ikola O, Granfors K. Increased synovial endothelium binding and transendothelial migration of mononuclear cells during Salmonella infection. Arthritis Rheum 1998;41:1054-1063.
72. 72. Yu DT, Choo SY, Schaack T. Molecular mimicry in HLA-B27-related arthritis. Ann Int Med 1989;111:581-591.
73. 73. Huang F, et al. A patient-derived cytotoxic T-lymphocyte clone and two peptide-dependent monoclonal antibodies recognize HLA-B27-peptide complexes with low stringency for peptide sequences. Infect Immun 1996;64:120-127.
74. 74. Sidrauski C, Chapman R, Walter P. The unfolded protein response - an intracellular signalling pathway with many surprising features. Trends Cell Biol 1998;8:245-249.
75. 75. Tirasophon W, Welihinda AA, Kaufman RJ. A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Irelp) in mammalian cells. Genes Dev 1998;12:1812-1824.
76. 76. Arnett FC. HLA and the spondylarthropathies. In: Calin A, ed. Spondylarthropathies. Orlando (FL): Grune & Stratton; 1984. p. 297-321.
77. 77. Amor B, Dougados M, Mijiyawa M. Critères de classification des spondyloarthropathies. Rev Rhum Mal Osteoartic 1990;57:85-89.
78. 78. Dougados M, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-1227.
79. 79. Bergfeldl L. HLA-B27-associated cardiac disease. Ann Intern Med 1997;127:621-629.
80. 80. McCutcheon JA, Lutz CT. Mutagenesis around residue 176 on HLA-B*0702 characterizes multiple distinct epitopes for anti-HLA antibodies. Hum Immunol 1992;35:125-131.
81. 81. Steinle A, Nossner E, Schendel DJ. Isolation and characterization of a genomic HLA-Cw6 clone. Tissue Antigens 1992;39:134-137.
82. 82. El-Zaatari F, Sams KC, Taurog JD. In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substituted side chain. J Immunol 1990;144:1512-1517.
83. 83. Dijkema R, van der Meide PH, Pouwelt PH. Cloning and expression of the immune interferon gene of the rat. EMBO J 1985;4:761-767.